Recent events
Recent events tied to this brand in public sources.
Back to profile6 entries
2020
Heji Pharmaceutical completes Series A funding
Heji Pharmaceutical announced that it completed a 280 million yuan Series A financing, with Baitai Pharma, Hisun Pharmaceutical, Tigermed, and Pucheng Investment among the investors.
2020
Shanghai Stock Exchange questions Haizheng Pharma's restructuring disclosure
The Shanghai Stock Exchange issued Haizheng Pharma a letter seeking explanations and supplementary disclosure on eight matters in its proposed restructuring plan, including the transaction's rationale, financing and target-company business and financial information.
2020
Hisun Pharmaceutical announces planned acquisition of a 49% stake in Hanhui Pharmaceutical
Hisun Pharmaceutical announced that it was planning a major asset restructuring to acquire a 49% stake in Hanhui Pharmaceutical from HPPC through a share issuance, convertible corporate bonds and cash, and to raise supporting funds. The transaction was described as planned, not completed.
2020
Shengzhao Pharmaceutical and Hisun signed a contract manufacturing agreement
Shengzhao Pharmaceutical announced that it had signed a contract manufacturing agreement with Hisun Pharmaceutical for two liposomal products.
2020
圣兆药物 and 海正药业 expand active-ingredient cooperation
圣兆药物 and 海正药业 signed a contract under which 圣兆药物 commissioned 海正药业 to develop the production process for sterile aripiprazole monohydrate active ingredient. The companies will jointly produce process-validation batches at a contract manufacturing site designated by 圣兆药物.
2020
Haizheng Pharma subsidiary and Anbisheng terminate cooperation agreements
Haizheng Pharma announced that the parties reached a settlement and that their exclusive distribution, distribution-and-purchase, and supplemental agreements would terminate effective when the settlement agreement took effect.